Mesothelioma

The FDA granted orphan drug designation to SynKIR-110, an investigational chimeric antigen receptor T-cell therapy, for treatment of mesothelin-expressing mesothelioma.

Rare Disease Day is Feb. 28.

Memorial Sloan Kettering Cancer Center placed a pause on a phase 1 clinical trial of ATA2271 — a chimeric antigen receptor T-cell therapy — after one patient treated with the investigational therapy died.

In this video, Karen M. Winkfield, MD, PhD, discusses how the annual Chemotherapy Foundation Symposium “address[es] all cancers, across the board.”

Chimeric antigen receptor T-cell therapy followed by pembrolizumab appeared safe and feasible for patients with malignant pleural mesothelioma, phase 1 trial results published in Cancer Discovery showed.

The combination of nivolumab and ipilimumab maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results.

Access to care varied significantly among patients with stage I to stage III malignant pleural mesothelioma, according to study results.

Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer.

Use of atezolizumab as part of neoadjuvant therapy and again as maintenance met predetermined safety criteria for patients with resectable pleural mesothelioma, according to study results.

Atezolizumab plus bevacizumab appeared well-tolerated and resulted in a 40% objective response rate among patients with malignant peritoneal mesothelioma, according to phase 2 study results published in Cancer Discovery.